research Dutasteride
Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
research Maximum Efficacy of Finasteride Is Obtained Within 6 Months and Maintained Over 6 Years
Finasteride works best in 6 months and lasts 6 years.
research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
Using finasteride with TIP extends time off period for prostate cancer patients.
research Clinical Applications of Antiandrogens
Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.
research Relationship Between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.
research Androgenetic Alopecia as an Early Marker of Benign Prostatic Hyperplasia
Early hair loss may indicate prostate issues.
research Continued Improvement in Pressure-Flow Parameters in Men Receiving Finasteride for 2 Years
Finasteride improves urinary function in men for 2 years.
research Testosterone Therapy in Men: Clinical and Pharmacological Perspectives
Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.
research Finasteride: The First 5α-Reductase Inhibitor
Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
research Apocrine Sweat Gland Obstruction by Antiperspirants Allowing Transdermal Absorption of Cutaneous Generated Hormones and Pheromones as a Link to the Observed Incidence Rates of Breast and Prostate Cancer in the 20th Century
The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.
research Recent Discoveries and Developments of Androgen Receptor-Based Therapy for Prostate Cancer
New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
research Women's Health Care During the Perimenopause
The document concludes that low-dose oral contraceptives and hormonal therapies can manage perimenopause symptoms and reduce some health risks, but lifestyle changes and disease screening are also important.
research New Biomarkers to Evaluate Hyperandrogenemic Women and Hypogonadal Men
The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.
research Finasteride for Prostatic Disease: An Updated and Comprehensive Review
Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
research Interactions Between Lower Urinary Tract Symptoms and Cardiovascular Risk Factors Determine Distinct Patterns of Erectile Dysfunction: A Latent Class Analysis
Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.
research Androgenetic Alopecia at Various Ages and Prostate Cancer Risk in an Equal-Access Multiethnic Case-Control Series of Veterans
Early balding, especially frontal, increases prostate cancer risk; more research needed.
research Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?
No definitive link between finasteride and male breast cancer, but further research is needed.
research The Long-Term Effect of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo-Controlled Trial
Finasteride doesn't harm bone density in older men with BPH.
research Current Treatment of Benign Prostatic Hyperplasia
TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
research Finasteride
Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
research Inappropriate Sexual Behaviors in Patients with Vascular Dementia: Possible Response to Finasteride
Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.
research Case-Only Trees and Random Forests for Exploring Genotype-Specific Treatment Effects in Randomized Clinical Trials with Dichotomous End Points
Case-only trees and random forests improve predictions of treatment effects in clinical trials.
research 5α-Reductase Inhibitors: Progress and Therapeutic Potential
5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
research Imaging Prostate Cancer With Technetium-99m Tricarbonyl Finasteride Dithiocarbamate
A new compound was effective for imaging prostate cancer in rats.
research Terazosin or Baclofen in Young Men with Chronic Orchialgia: A Cohort Study of 499 Patients
Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.
research Dutasteride: A Review of Its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research Can We Predict Prostate Size by Scoring Baldness? The Relationship of Androgenic Alopecia and Lower Urinary Tract Symptoms
Baldness score can't be used to predict prostate size.
research PSA Test Sensitized by Finasteride
Finasteride improves prostate cancer detection in PSA test.
research Medical Management of Benign Prostatic Hyperplasia
Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.